Dual Pathway Inhibition in Patients with Atherosclerosis with or without Heart Failure: Insights from the XATOA Registry
Background: Patients with atherosclerotic cardiovascular disease might benefit from dual pathway inhibition (DPI) therapy, which includes rivaroxaban and aspirin. Patients with concomitant heart failure (HF) are a subgroup with a higher risk for ischemic events. Accordingly, we explored the risks an...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-04-01
|
| Series: | CJC Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589790X25000411 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|